Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BRII 198

Drug Profile

BRII 198

Alternative Names: BRII-198

Latest Information Update: 23 Apr 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Third People's Hospital of Shenzhen; Tsinghua University
  • Developer Brii Biosciences; National Institute of Allergy and Infectious Diseases; TSB Therapeutics (Beijing) CO.LTD
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III COVID 2019 infections

Most Recent Events

  • 23 Apr 2021 Brii Biosciences and TSB Therapeutics completes a phase I trial for COVID-2019 infections (In volunteers) in China (IV) (NCT04479644)
  • 08 Mar 2021 Brii Biosciences plans a phase II trial in combination with BRII 196 for COVID-2019 infections (In adults, Combination therapy) in China (NCT04787211)
  • 04 Mar 2021 Brii Biosciences files an IND application with the Department of Health in Hong Kong for COVID-2019 infections before March 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top